Veteran Medical Device Executive Set to Lead Transcatheter Valve Company Organization
MAPLE GROVE, Minn. (June 2, 2021) – HLT Inc., a Bracco Group Company, leading the development of cutting edge transcatheter aortic valve replacement (TAVR) therapy, has appointed David Elizondo as president and CEO. In his new role, Elizondo will lead the development and execution of HLT’s operational and strategic business objectives and milestones.
“I, along with the Bracco leadership, have been very impressed by the path the company has taken over the past year and a half and the great progress that has been made with David leading the team,” said Bradley Fox, president and CEO of ACIST Medical Systems, Inc. and vice chairman of the board of directors for HLT. “We believe David’s expertise in product development and operational leadership within interventional cardiology, cardiac surgery, and structural heart will drive the clinical advancement and success of the HLT® Meridian® TAVR Valve System.”
Elizondo has more than 30 years of medical device and business expertise through a range of different career experiences. As part of the HLT family, he transitions from the role of senior vice president, research and development and general manager to president and CEO. Focused in the areas of structural heart, he has served as chief operating officer at Direct Flow Medical, Inc., vice president of research, development, and clinical affairs at ATS Medical, Inc., and has held various leadership positions within the United States, Europe and South America in technology, research, and business development at Coloplast, Inc., St. Jude Medical, Inc. and Boston Scientific Corp.
“Our team has made tremendous progress over the past year. We have the right technology, people, and plan in place to provide improved care for our patients,” said Elizondo. “We are very encouraged by the current testing and excited to start our upcoming clinical phases as we obtain the necessary approvals. I am proud to be part of this strong, highly experienced medical device team as we move into our next phases. This is a very exciting time to be leading HLT.”
Elizondo holds a Bachelor of Science degree in Biomedical Engineering from the Milwaukee School of Engineering and a Master of Science degree in Biomedical Engineering from the University of Iowa. He has also completed advanced technology and management studies at both the University of Iowa and the University of St. Thomas.
HLT is committed to advancing TAVR therapies to improve lives. This will occur through innovation, technologies, and procedural techniques designed to achieve better, more predictable patient outcomes and improve the quality of life for TAVR patients.
With global headquarters in Maple Grove, Minn., HLT employs highly experienced healthcare and device industry professionals working in a creative, collaborative and entrepreneurial environment.
As part of the Bracco Group, HLT benefits from the resources of a multinational conglomerate with broad expertise in cath lab technology and a dedication to continuous advancement. Bracco invests a significant amount of its resources in research and innovation across its portfolio of companies to improve patient outcomes and optimize treatment procedures.
To learn more about HLT, visit www.hltmedical.com.
About Bracco Group
Bracco is headquartered in Milan, Italy, and was founded in 1927. It is active in the healthcare sector through Bracco Imaging (diagnostic imaging), ACIST Medical Systems and HLT (cardiology) and the Centro Diagnostico Italiano diagnostic clinic. It has around 3,600 employees and annual total consolidated revenues of around 1.5 billion euros. Bracco operates in more than 100 countries worldwide. To learn more about Bracco Group, visit www.bracco.com.
Investigational device. Not available for sale in any geography.